All articles tagged with #t cells
New experiments in humans and mice show T cells become more capable after a meal: post-meal T cells more readily access nutrients, boosting their activation, proliferation, and ability to fight infection within about six hours after eating, with potential implications for vaccine timing and immune therapies.
In mice, blocking the Ant2 protein reprograms T cell energy metabolism, boosting their endurance and ability to detect and destroy cancer cells, a finding that could lead to metabolism-based immunotherapies.
New Nature studies from Aarhus University suggest the thymus—a small immune organ once thought to fade after youth—continues to influence disease risk and how well patients respond to cancer immunotherapy. Better thymus function linked to improved treatment outcomes and longer survival; its decline is accelerated by smoking, obesity, and low activity, pointing to prevention angles and potential for tailoring cancer therapies by patients’ immunological status.
A phase 1 trial in 41 patients with recurrent glioblastoma found that a single injection of a modified herpes simplex virus can kill tumor cells and recruit enduring T cell activity into the tumor, correlating with longer survival than historical outcomes.
Dietary lipid composition (PUFAs/MUFAs) determines mouse T cell resistance to ferroptosis, shaping T cell homeostasis and immune responses via lipid remodeling; these diet‑induced ferroptosis effects (DEFs) are microbiota‑independent and correlate with human plasma lipid profiles, with PUFA‑containing phospholipids driven by ACSL4 underpinning TFH cell development and broader T cell–mediated immunity, including anti‑tumor responses and CAR‑T therapy. The findings suggest targeting lipid metabolism could enhance vaccines and immunotherapies.
A nasal vaccine candidate that trains frontline lung immunity shows promise in mice for broad protection against multiple respiratory infections (cold viruses, flu, and COVID) by boosting alveolar macrophages and T cells rather than targeting a single pathogen; it may also dampen allergic reactions. Human safety and efficacy remain unproven, and the best-case path to a human-ready vaccine is five to seven years, with protection in mice lasting up to about three months and many unknowns, including effects in older adults and on DNA viruses.
A phase study in 14 women with adjuvant-treated triple-negative breast cancer shows individualized neoantigen mRNA–LPX vaccines encoding up to 20 mutations elicit robust, multi-epitope CD4+/CD8+ T cell responses that persist for years and correlate with relapse-free outcomes in most patients (up to ~6 years). Vaccinated T cells differentiate into cytotoxic, late-stage effector and stem-like memory (TSCM) phenotypes, with durable clonal lineages detected long after vaccination. Three relapses occurred due to weak responses, MHC I loss, or a genetically distinct recurrent tumor. The findings demonstrate the feasibility of on-demand personalized RNA vaccines and provide insights into immune escape and memory formation to guide future immunotherapy strategies.
Texas A&M researchers report a chemogenetic system that links CRISPR activity to caffeine, enabling controllable, reversible gene editing and T‑cell activation via a “caffebody,” with safety shutoffs using rapamycin. This approach aims for more precise cancer therapies and other long‑term treatments, pending further preclinical studies.
MIT researchers demonstrated in aging mice that delivering mRNA encoding key immune-signaling pathways causes the liver to transiently manufacture factors that boost thymus-driven T-cell production. This rejuvenation improved immune responses to vaccines and cancer immunotherapy with minimal side effects, and slowed tumor progression in treated mice. The therapy has not been tested in humans and would require ongoing injections to maintain benefits, but it represents a potential approach to counteract age-related immune decline and possibly broader aging processes.
Broad Institute researchers show in old mice that injecting mRNA into the liver triggers thymic signals (DLL1, FLT3-L, IL-7), reviving T-cell production. Over four weeks, older mice had more diverse T cells, stronger vaccine responses, and better anti-cancer activity, though the boost was temporary and human trials are needed, with the findings published in Nature.
UBC researchers show that precisely tuning the duration and intensity of Notch signaling in stem cells can reliably steer them to become helper or killer T cells, enabling scalable, off-the-shelf immunotherapies for cancer and other diseases. This overcomes a long-standing bottleneck by producing both T cell types from renewable sources, potentially reducing manufacturing costs and time.
Scientists at the University of Southampton developed a four-armed antibody that enhances T cell activation by clustering immune receptors, significantly boosting the immune response against cancer in laboratory tests, offering a promising new approach for cancer immunotherapy.
A mouse study demonstrates that an experimental mRNA treatment can rejuvenate immune cells, specifically T cells, potentially improving immune response in aging, but further research is needed to assess its applicability in humans.
MIT researchers have developed a method to temporarily boost immune function in aging by reprogramming liver cells to produce T-cell supporting signals, improving immune responses and potentially helping older adults stay healthier longer.
A study demonstrates that a twice-weekly cocktail of three messenger RNAs can rejuvenate aged immune cells in mice, particularly T cells, enhancing their response to vaccines and cancer therapies, by targeting T cells through the liver to counteract age-related decline and thymus degradation.